UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000045040
Receipt No. R000051446
Scientific Title A confirmation study for improving cognitive function with consumption of the test food: A randomized double-blind placebo-controlled trial
Date of disclosure of the study information 2021/08/02
Last modified on 2022/06/28 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A confirmation study for improving cognitive function with consumption of the test food
Acronym A confirmation study for improving cognitive function with consumption of the test food
Scientific Title A confirmation study for improving cognitive function with consumption of the test food: A randomized double-blind placebo-controlled trial
Scientific Title:Acronym A confirmation study for improving cognitive function with consumption of the test food
Region
Japan

Condition
Condition Healthy Japanese subjects
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the effects of consumption of the test food on cognitive function in healthy Japanese men and women aged 40 or more
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes The measured value of the standardized score of composite memory at 12 weeks after consumption (12w)
Key secondary outcomes 1. The amount of change of the standardized score of composite memory between screening (before consumption; Scr) and 12w

2. The measured values of the standardized scores of Neurocognition Index (NCI), verbal memory, visual memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, executive function, social acuity, reasoning, working memory, sustained attention, simple attention and motor speed at 12w

3. The amounts of changes of the standardized scores of NCI, verbal memory, visual memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, executive function, social acuity, reasoning, working memory, sustained attention, simple attention and motor speed between Scr and 12w

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Duration: 12 weeks
Test food: Food containing Citrus depressa extract powder
Administration: Take one capsule with water after breakfast

* Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_2 Duration: 12 weeks
Test food: Food not containing Citrus depressa extract powder
Administration: Take one capsule with water after breakfast

* Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Japanese

2. Men or women

3. Subjects aged 40 or more

4. Healthy subjects

5. Subjects who are aware of the decline in their memory function

6. Subjects who are judged as eligible to participate in the study by the physician

7. Subjects whose scoring of Mini Mental State Examinination (MMSE)-J is 24 or more

8. Subjects who have a "yes" in the validity indicator of Cognitrax on both verbal memory and visual memory

9. Subjects who have a relatively low standardized score of composite memory by Cognitrax
Key exclusion criteria Subjects who

1. are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction

2. have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. have dementia

5. have mental health issues such as depression disorder, attention deficit/hyperactivity disorder (ADHD), or other issues

6. are smoker at the time of the agreement to participate in this trial or plan to smoke during this trial

7. plan to have surgery from first consumption to two weeks after last consumption

8. take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage at least four times a week

9. take supplements related to improving cognitive functions, such as docosahexaenoic acid, eicosapentaenoic acid, ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid, phosphatidylserine, and plasmalogen at least four times a week

10. take blue-backed fish such as sardines, mackerel, and saury at least four times a week

11. use devices, equipment, and applications that may affect cognitive functions (e.g., brain training puzzles, brain training games) in daily

12. are currently taking medications (including herbal medicines) and supplements

13. are allergic to medications and/or the test-food-related products (particularly citrus fruit)

14. are pregnant, lactation, or planning to become pregnant

15. have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial

16. are judged as ineligible to participate in the study by the physician
Target sample size 36

Research contact person
Name of lead principal investigator
1st name Tsuyoshi
Middle name
Last name Takara
Organization Medical Corporation Seishinkai, Takara Clinic
Division name Director
Zip code 141-0022
Address 9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL 03-5793-3623
Email t-takara@takara-clinic.com

Public contact
Name of contact person
1st name Naoko
Middle name
Last name Suzuki
Organization ORTHOMEDICO Inc.
Division name R&D Department
Zip code 112-0002
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL 03-3818-0610
Homepage URL
Email nao@orthomedico.jp

Sponsor
Institute ORTHOMEDICO Inc.
Institute
Department

Funding Source
Organization Okinawa TLO Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic
Name of secondary funder(s)

IRB Contact (For public release)
Organization the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
Tel 03-5793-3623
Email IRB@takara-clinic.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)

Other administrative information
Date of disclosure of the study information
2021 Year 08 Month 02 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 40
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2021 Year 07 Month 29 Day
Date of IRB
2021 Year 07 Month 29 Day
Anticipated trial start date
2021 Year 08 Month 03 Day
Last follow-up date
2022 Year 01 Month 23 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 08 Month 02 Day
Last modified on
2022 Year 06 Month 28 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051446